Chemotherapy for diffuse large B-cell lymphoma is more effective, with more than 70% of diffuse large B-cell lymphomas going into remission after chemotherapy, but ultimately only 50% to 60% of patients will have long-term disease-free survival. Diffuse large B-cell lymphoma is an aggressive lymphoma, referred to as DLBCL, and chemotherapy regimens include the CHOP regimen and the R-CHOP regimen.CHOP is the standard treatment regimen, with a course of treatment every 2 to 3 weeks, and this regimen has a 5-year disease-free survival rate of 41% to 80%. The R-CHOP regimen, i.e., the addition of rituximab before chemotherapy, can achieve better efficacy and is the classic regimen for the treatment of DLBCL. The results of nearly ten years of follow-up indicated that this regimen prolonged the overall survival time of DLBCL patients by 4.9 years. If you are diagnosed with DLBCL, you should actively cooperate with doctors for treatment, keep optimistic attitude, and achieve early diagnosis and early treatment. Avoid exertion and pay attention to rest in life.